Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis

Journal of Rheumatology

Volumn 32, Issue 8, 2005, Pages 1620-1631

  Kalden, Joachim R ^a   Antoni, Christian ^b   Álvaro Gracia, Jose M ^c   Combe, Bernard ^d   Emery, Paul ^e   Kremer, Joel M ^f   Strand, C Vibeke ^g   Van Riel, Piet L C M ^h   Smolen, Josef S ⁱ  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Medizinische Klinik III   (Germany)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d LAPEYRONIE HOSPITAL   (France)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f Center for Rheumatology LLP   (United States)

^g STANFORD UNIVERSITY   (United States)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ GENERAL HOSPITAL LINZ   (Austria)

Author keywords

Combination treatment; Efficacy; Leflunomide; Rheumatoid arthritis; Tolerability; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ANTIMALARIAL AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ALOPECIA; ANAPHYLAXIS; ANGINA PECTORIS; ARTHRALGIA; AUTOIMMUNE DISEASE; CELLULITIS; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DECISION MAKING; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRY SKIN; ECZEMA; EDEMA; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEART FAILURE; HERPES ZOSTER; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; INJECTION SITE REACTION; KNEE PAIN; LEG EDEMA; LIVER DISEASE; MELANOMA; MONOTHERAPY; MYALGIA; MYELODYSPLASIA; NAUSEA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RESPIRATORY DISTRESS SYNDROME; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SYNCOPE; THORAX PAIN; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES;

EID: 23444461026     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (41)

1. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50.
2. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.
3. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology Oxford 2000;39:655-65.
4. Osiri M, Shea B, Robinson V, et al. Leflunomide for the treatment of rheumatoid arthritis: A systematic review and meta analysis. J Rheumatol 2003;30:1182-96.
5. Li EK, Tam LS, Tomlinson B. Leflunomide in the treatment of rheumatoid arthritis. Clin Ther 2004;26:447-59.
6. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2004;50:1939-50.
7. Smolen JS. Practical management of rheumatoid arthritis patients treated with leflunomide. An international expert panel meeting. J Rheumatol 2004;31 Suppl 71:1-12.
8. Smolen JS, Emery P, Kalden JR, et al. The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. J Rheumatol 2004;31 Suppl 71:13-20.
9. Kalden JR, Smolen JS, Emery P, et al. Lefunomide in combination therapy. J Rheumatol 2004;31 Suppl 71:25-30.
10. van Riel PL, Smolen JS, Emery P, et al. Leflunomide: a manageable safety profile. J Rheumatol 2004;31 Suppl 71:21-4.
11. Kiely PD, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology Oxford 2002;41:631-7.
12. Cherwinski HM, Cohn RG, Cheung P, et al. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995;275:1043-9.
13. Greene S, Watanabe K, Braatz-Trulson J, Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochem Pharmacol 1995;50:861-7.
14. Ruckemann k, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998;273:21682-91.
15. Cutolo M, Sulli A, Ghiorzo P, Pizzorni C, Craviotto C, Villagio B. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:297-302.
16. Feldmann M, Brennan F, Paleolog E, Taylor P, Maini RN. Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action. Eur Cytokine Netw 1997;8:297-300.
17. Paleolog E. The therapeutic potential of TNF-alpha blockade in rheumatoid arthritis. Expert Opin Investig Drugs 2003;12:1087-95.
18. Goffe B, Cather JC. Etanercept: An overview. J Am Acad Dermatol 2003;49 Suppl:S105-11.
19. den Broeder AA, Joosten LA, Saxne T, et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. Ann Rheum Dis 2002;61:311-8.
20. Schiff MH. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis 2000;59 Suppl 1:i103-8.
21. Dayer JM. Evidence for the biological modulation of IL-1 activity: the role of IL-1Ra. Clin Exp Rheumatol 2002;20 Suppl 27:S14-20.
22. Hansen KE, Cush J, Singhal A, et al. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum 2004;51:228-32.
23. Patel S, Bergen W, Kraemer A, Keenan GF. Efficacy and safety of remicade (infliximab) plus arava (leflunomide) in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001;44 Suppl:S84.
24. Perdriger A, Combe B, Kuntz JL, et al. A French multicenter retrospective study on the efficacy and safety of infliximab in association with DMARDs other than methotrexate [abstract]. Ann Rheum Dis 2004;50 Suppl:488.
25. Godinho F, Godfrin B, El Mahou S, Navaux F, Zabraniecki L, Cantagrel A. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol 2004;22:328-30.
26. Ortiz Garcia AM, Gonzalez-Alvaro I, Rosello Pardo R, Carmona L, Fabregas Canales MD, Monteagudo Saez I. Infliximab and Leflunomide Study Group. Effectiveness and safety of infliximab combined with leflunomide in chronic polyarthritis [letter]. Clin Exp Rheumatol 2004;22:790.
27. Struppler CI, Thies W, Schattenkirchner M, Kellner H. Safety and efficacy of leflunomide and infliximab in rheumatoid arthritis (RA) patients [abstract]. Ann Rheum Dis 2002;61:S388.
28. Bingham SJ, Buch MH, Kerr MA, Emery P, Valadao Barcelos AT. Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. Arthritis Rheum 2004;50:4072-3.
29. Flendrie M, Creemers MC, Welsing PM, van Riel PL. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. Rheumatology Oxford 2005;44:472-8.
30. Antoni C, Manger B. Treatment of psoriatic arthritis with TNF alpha-antagonists. Z Rheumatol 2003;62:235-9.
31. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003;30:2563-71.
32. Tesser J, Fleischmann R, Dore R, et al. Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. J Rheumatol 2004;31:649-54.
33. De Rycke L, Peene I, Hoffman IE, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63:1587-93.
34. Garnero P, Landewe R, Boers M, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002;46:2847-56.
35. de Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Van Zeben D, et al. BeSt Trial Group. A comparison of clinical and radiological outcomes of four treatment strategies for early rheumatoid arthritis: results of the BeSt trial [abstract]. EULAR Meeting, Berlin, Germany, 2004: 0P0001. [Internet] Accessed April 14, 2005. Available from http://www.eular.org/index.cfm?framePage=/ eular2004.cfm.
36. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363:675-81.
37. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42.
38. Cunnane G, Warnock M, Fye KH, Daikh DI. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum 2002;47:445-9.
39. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. Rheumatology Oxford 2002;41:116-7.
40. Macdonald J, Zhong T, Lazarescu A, Gan BS, Harth M. Vasculitis associated with the use of leflunomide. J Rheumatol 2004;31:2076-8.
41. Mockenhaupt M, Kelly JP, Kaufman D, Stern RS; SCAR Study Group. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol 2003;30:2234-40.